Join Growin Stock Community!

Pmgc holdings inc.ELAB.US Overview

US StockHealthcare
(No presentation for ELAB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ELAB AI Insights

ELAB Overall Performance

ELAB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ELAB Recent Performance

-2.48%

Pmgc holdings inc.

0.05%

Avg of Sector

-0.31%

S&P500

ELAB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ELAB Key Information

ELAB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ELAB Profile

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

Price of ELAB

ELAB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ELAB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-63.17
PE Ratio (TTM)
0.01
Forward PE
-
PS Ratio (TTM)
4.93
PB Ratio
0.18
Price-to-FCF
0.00
METRIC
VALUE
vs. INDUSTRY
Gross Margin
82.15%
Net Margin
458.39%
Revenue Growth (YoY)
-159.75%
Profit Growth (YoY)
-168.99%
3-Year Revenue Growth
-12.86%
3-Year Profit Growth
-30.86%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-63.17
PE Ratio (TTM)
0.01
Forward PE
-
PS Ratio (TTM)
4.93
PB Ratio
0.18
Price-to-FCF
0.00
Gross Margin
82.15%
Net Margin
458.39%
Revenue Growth (YoY)
-159.75%
Profit Growth (YoY)
-168.99%
3-Year Revenue Growth
-12.86%
3-Year Profit Growth
-30.86%
  • When is ELAB's latest earnings report released?

    The most recent financial report for Pmgc holdings inc. (ELAB) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ELAB's short-term business performance and financial health. For the latest updates on ELAB's earnings releases, visit this page regularly.

  • What is the operating profit of ELAB?

    According to the latest financial report, Pmgc holdings inc. (ELAB) reported an Operating Profit of -2.2M with an Operating Margin of -768.99% this period, representing a decline of 139.28% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ELAB's revenue growth?

    In the latest financial report, Pmgc holdings inc. (ELAB) announced revenue of 285.95K, with a Year-Over-Year growth rate of -45.79%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ELAB have?

    As of the end of the reporting period, Pmgc holdings inc. (ELAB) had total debt of 4.41M, with a debt ratio of 0.3. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ELAB have?

    At the end of the period, Pmgc holdings inc. (ELAB) held Total Cash and Cash Equivalents of 7.7M, accounting for 0.52 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ELAB go with three margins increasing?

    In the latest report, Pmgc holdings inc. (ELAB) did not achieve the “three margins increasing” benchmark, with a gross margin of 27.3%%, operating margin of -768.99%%, and net margin of -907.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ELAB's profit trajectory and future growth potential.

  • Is ELAB's EPS continuing to grow?

    According to the past four quarterly reports, Pmgc holdings inc. (ELAB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -4.91. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ELAB?

    Pmgc holdings inc. (ELAB)'s Free Cash Flow (FCF) for the period is -1.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 99.95% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.